Aptamer:toxin conjugates that specifically target prostate tumor cells

Ted C. Chu, John W. Marks, Laura A. Lavery, Sarah Faulkner, Michael G. Rosenblum, Andrew D. Ellington, Matthew Levy

Research output: Contribution to journalArticle

237 Scopus citations


We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets.

Original languageEnglish (US)
Pages (from-to)5989-5992
Number of pages4
JournalCancer Research
Issue number12
StatePublished - Jun 15 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Aptamer:toxin conjugates that specifically target prostate tumor cells'. Together they form a unique fingerprint.

  • Cite this

    Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Research, 66(12), 5989-5992. https://doi.org/10.1158/0008-5472.CAN-05-4583